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Abstract
Background: Opioids, such as heroin, kill more people worldwide by overdose than any other type of drug, and
death rates associated with opioid poisoning in the UK are at record levels (World Drug Report 2018 [Internet].
[cited 2019 Nov 19]. Available from: http://www.unodc.org/wdr2018/; Deaths related to drug poisoning in
England and Wales - Office for National Statistics [Internet]. [cited 2019 Nov 19]. Available from: https://www.
ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrug
poisoninginenglandandwales/2018registrations). Naloxone is an opioid antagonist which can be distributed in
‘kits’ for administration by witnesses in an overdose emergency. This intervention is known as take-home
naloxone (THN). We know that THN can save lives on an individual level, but there is currently limited evidence
about the effectiveness of THN distribution on an aggregate level, in specialist drug service settings or in
emergency service settings. Notably, we do not know whether THN kits reduce deaths from opioid overdose in
at-risk populations, if there are unforeseen harms associated with THN distribution or if THN is cost-effective. In
order to address this research gap, we aim to determine the feasibility of a fully powered cluster randomised
controlled trial (RCT) of THN distribution in emergency settings.
Methods: We will carry out a feasibility study for a RCT of THN distributed in emergency settings at four sites,
clustered by Emergency Department (ED) and catchment area within its associated ambulance service. THN is a
peer-administered intervention. At two intervention sites, emergency ambulance paramedics and ED clinical
staff will distribute THN to adult patients who are at risk of opioid overdose. At two control sites, practice will
carry on as usual. We will develop a method of identifying a population to include in an evaluation, comprising
people at risk of fatal opioid overdose, who may potentially receive naloxone included in a THN kit.
We will gather anonymised outcomes up to 1 year following a 12-month ‘live’ trial period for patients at risk of
death from opioid poisoning. We expect approximately 100 patients at risk of opioid overdose to be in contact
with each service during the 1-year recruitment period. Our outcomes will include deaths, emergency
admissions, intensive care admissions, and ED attendances. We will collect numbers of eligible patients
attended by participating in emergency ambulance paramedics and attending ED, THN kits issued, and NHS
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resource usage. We will determine whether to progress to a fully powered trial based on pre-specified
progression criteria: sign-up of sites (n = 4), staff trained (≥ 50%), eligible participants identified (≥ 50%), THN
provided to eligible participants (≥ 50%), people at risk of death from opioid overdose identified for inclusion
in follow-up (≥ 75% of overdose deaths), outcomes retrieved for high-risk individuals (≥ 75%), and adverse
event rate (< 10% difference between study arms).
Discussion: This feasibility study is the first randomised, methodologically robust investigation of THN
distribution in emergency settings. The study addresses an evidence gap related to the effectiveness of THN
distribution in emergency settings. As this study is being carried out in emergency settings, obtaining informed
consent on behalf of participants is not feasible. We therefore employ novel methods for identifying
participants and capturing follow-up data, with effectiveness dependent on the quality of the available routine
data.
Trial registration: ISRCTN13232859 (Registered 16/02/2018)
Background
Accidental overdose related to the misuse of opioid
drugs is an increasingly prevalent public health problem,
and opioid-related deaths are at record levels in both the
UK and North America [1, 2].
People who misuse either illicit or prescription opioids
are at an increased risk of non-fatal overdose, subsequent
hospital or emergency service utilisation, and death [3–5].
Non-fatal opioid overdose is associated with long-term
morbidity and increased demand on health services [6, 7].
Emergency service contact for drug-related morbidity has
been found to be a predictor of future episodes of poison-
ing or overdose [8, 9].
Naloxone is an opioid antagonist used to treat opioid
overdose. Naloxone can be supplied to people at risk of
opioid overdose by paramedics [10] or by laypeople in
the form of take-home naloxone (THN). Typically, a
THN kit comprises one or more doses of naloxone, an
intramuscular needle and syringe for administering the
dose, and written or pictorial instructions to explain
how to prepare and administer the dose, perform basic
life support, and the importance of calling the emer-
gency services. These materials may also describe the
duration of effect and hence why it is important that
paramedics attend the patient as soon as possible, the
safety of naloxone in terms of adverse events and over-
dose, and the legality of bystander administration of
naloxone.
Non-experimental studies suggest that THN programmes
which involve the training of laypersons to administer a na-
loxone dose in cases of overdose emergency are safe and ef-
fective [11, 12]. THN kits can be used by people without
formal medical training in the event of an opioid overdose.
Increased access to THN kits via specialist drug services in
the UK and internationally has been motivated by recom-
mendations from influential bodies, including the World
Health Organization (WHO) and the British Advisory
Council on the Misuse of Drugs (ACMD) [13, 14].
Numerous THN distribution programmes aiming to
reduce death from opioid overdose have been imple-
mented by drug service providers in the UK and inter-
nationally since the 1990s [15, 16]. However, a
significant proportion of people at risk of opioid over-
dose do not engage with these services [17]. Addition-
ally, high-quality empirical evidence to demonstrate the
safety and effectiveness of THN is sparse. Observational
data suggests that non-serious adverse reactions to na-
loxone administration are common while serious adverse
reactions are rare [18]. However, the risks of inadequate
response or return to a state of overdose following the
administration of naloxone by laypeople remain poorly
quantified [19, 20]. Moreover, the uptake of THN kits in
at-risk populations remains low [21, 22] and appropriate
THN intervention by peers and witnesses may not be
optimal [23].
Members of the research team (CM, HS) have previ-
ously conducted a randomised feasibility study of THN
distributed through the emergency ambulance service in a
single-urban geographic area [24]. Their experiences, con-
sistent with those of other researchers [25], have demon-
strated that using traditional methods (e.g., telephone or
postal methods) for capturing follow-up outcomes of par-
ticipants in receipt of a THN kit (and of those not in re-
ceipt of a THN kit despite eligibility) is not feasible.
This paper describes a protocol for a feasibility study
of THN distributed in the Emergency Department (ED)
and catchment area within its associated emergency
ambulance service. In carrying out the proposed study,
we seek to determine the feasibility of carrying out a
fully powered cluster randomised controlled trial (RCT)
of THN in emergency settings using routinely collected,
anonymised, and linked data to capture outcomes.
Should we find that carrying out a full trial is feasible,
this subsequent trial would be adequately powered to
determine the safety, clinical, and cost-effectiveness of
THN distribution in emergency settings.
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Methods
Setting, recruitment, and consent
We will carry out a feasibility study in the emergency
care environment, involving study sites defined geo-
graphically as an ED and its catchment area within the
local emergency ambulance service. For example, one
study site comprises the ED at Bristol Royal Infirmary, a
large city centre hospital in England, and its catchment
area, the surrounding urban area from which the South
West Ambulance Service Foundation Trust routinely
conveys patients to this ED. The study will be delivered
in the form of an RCT clustered by study site, using
retrospective anonymised linked routine data to capture
patient outcomes. We will also collect qualitative data to
gain an understanding of the processes of implementa-
tion of the intervention and experiences of service users
and providers. Finally, we will collect data related to
patient safety.
Participant recruitment
We cannot know if the naloxone dose included in any in-
dividual THN kit will be administered to a peer of the re-
cipient of the kit or to the recipient him/herself. Effects of
the THN intervention could extend beyond recipients
seen in the ED or by ambulance crews. Therefore, in order
to measure treatment effect in those likely to benefit from
THN, we define two populations: those eligible for receipt
of intervention (at intervention sites) and those at high
risk of death from opioid overdose at all sites.
Population A: eligible for receipt of THN (at intervention
sites)
Our first population is the target population for the
intervention, comprising adult patients who arrive at the
ED, or who are attended by ambulance paramedics for a
problem related to opioid misuse (e.g. opioid overdose
or injuries due to opioid use). ED clinicians and ambu-
lance service paramedics will undertake an initial clinical
assessment as per routine practice, and adults presenting
with an opioid misuse-related problem and with the cap-
acity to consent to receipt of the kit will be identified as
potentially eligible to receive THN. These patients will
be eligible to be offered THN following standard treat-
ment by a participating paramedic or ED clinician.
Patients who lack capacity, who are aggressive or exhibit
other challenging behaviour, who are seen by untrained
staff, who have already been recruited, or who are in cus-
tody at the time of their presentation will be excluded.
Population B: predicted to be at high risk of death from
opioid overdose
We will identify for inclusion in outcome follow-up
people at high risk of fatal opioid overdose who may be
able to benefit from naloxone from a THN kit. Population
B thus extends the target population for follow-up of out-
comes beyond original recipients of THN kits. We will de-
fine a discriminant function and use this as a predictive
tool, similar to a risk index, incorporating known and rou-
tinely recorded predictors of opioid-related events. We
will use existing linked data on opioid deaths in Wales, in-
cluding ED and in-patient data, to select predictors most
closely associated with those who died from opioid poi-
soning, and then use these predictors in our discriminant
function to identify participants in the study site areas to
be included in the ‘high-risk population’ (population B)
for outcome analyses. We previously carried out scoping
of NHS Wales ED and hospital routine datasets and linked
ONS mortality records with these datasets. We found that
we were able to describe circumstances of death for opioid
overdose decedents who had visited EDs prior to their
death, as well as describe service usage over a prolonged
observation period. Mortality data were of high quality, as
were data items on times and dates of attendances, out-
comes of attendances, and demographic characteristics of
attendees. Diagnostic and treatment data were of lower
quality. Routine data in England will be captured from
existing routine datasets as well as the recently imple-
mented ECDS (Emergency Care Data Set); we will assess
the quality of the data obtained from this source as a part
of the research.
As ambulance service records are not routinely in-
cluded in nationally available datasets that can be linked
anonymously, we will assess whether the inclusion of po-
tential participants from routine ambulance service data,
e.g. patient records including flags such as ‘naloxone ad-
ministered’ or ‘drug overdose’ improves the performance
of the predictive tool. If this is the case, these data will
be included in the final dataset used to identify the
population in whom outcomes will be compared be-
tween intervention and control sites.
We will gather prospective clinical data at each inter-
vention site related to eligibility and distribution of THN
kits. We will also gather retrospective and prospective data
from all participating ambulance services related to indica-
tors of the high risk of death from opioid overdose, e.g.
naloxone administration (for use in defining population
B). These data will be sent by participating ambulance ser-
vices and EDs using ‘split-file’ format to the National
Health Service (NHS) Digital in England and to the NHS
Wales Informatics Service (NWIS) in Wales (with identifi-
able data separated from clinical data) for matching and
linkage to routine centrally held datasets. All study data
will be transferred to the Secure Anonymised Information
Linkage (SAIL) Gateway for analysis [26].
Consent
We will not attempt to gain consent to participate in the
trial prospectively, at the time of attendance for opioid-
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related emergency, because that setting contradicts the
requirements of informed consent [27]. We will not
gather consent retrospectively, as the population is likely
to be very difficult to reach and low contact rates could
invalidate research findings. We will, however, consent
patients to receive the intervention. Patients will do this
by signing a training sheet, giving their name and date of
birth as part of this process. In this way, we will gather
some demographic information about the trainees and
have a written record confirming that participants were
trained to use the THN kit effectively.
As the wider population for inclusion in follow-up
(population B) will be identified through anonymised
routine data sources, we will not have identifiable data
with which to contact people for consent purposes. Ra-
ther, we will offer the option to dissent from the re-
search at all sites via patient information leaflets
supplied with THN kits and made available at ED wait-
ing areas. We will also include this information on the
Wales Centre for Primary and Emergency (including un-
scheduled) Care Research (PRIME) website www.prime-
centre.wales. We have gained ethical, research, and
information governance permissions to allow this study
to follow this approach, in which all information about
processes and outcomes of care will be anonymised to
the research team except for clinical members at each
site. These clinical researchers will split identifiable from
clinical and operational study data before sending files
separately to the NHS Digital in England and NWIS in
Wales for linkage to routinely held outcomes in ED, in-
patient, and mortality datasets held centrally; this split-
file approach in which identifiable and clinical data are
separated preserves patient anonymity [25].
For the qualitative component, we will obtain written
informed consent from all service users and health care
professionals who participate in interviews and focus
groups. Service user participants will be identified by
members of the NHS care team and third-sector drug
treatment services. Participants will also be eligible to re-
ceive a thank you gift card voucher for their time.
Sample size
We aim to include enough patients to test our study
methods, study intervention, and outcome data collec-
tion. Site enrolment and allocation, and follow-up of
participants prior to analysis are summarised in Fig. 1.
At each intervention site, with approximately 2000
people thought to be at high risk of fatal overdose, we
expect 200 to make contact with the ED or ambulance
service over the course of 1 year and be eligible to re-
ceive THN. We expect 100 contacts via the ED, and an-
other 100 contacts via the corresponding ambulance
service.
We will use routine linked data to identify the popula-
tion to be included at each site in outcome analyses via
a predictive model to be fully specified within our study.
The model will include opioid users who have made
contact with included services over a period of 24
months previous to our recruitment phase. Individuals
predicted to be at risk of death from opioid overdose will
include those attending ED or being attended by a 999
paramedic during the recruitment phase and their peers.
We expect the follow-up population to be at least 1520
people across four sites.
Randomisation
We approached all UK ambulance services and received
five positive responses from potential sites with matched
EDs, who were able to demonstrate the capacity and re-
sources to participate. Of these potential sites, four dem-
onstrated sufficient geographic separation from other
study sites to mitigate potential cross-contamination of
study populations. From these four sites, we selected
two to be intervention sites and two to be control sites;
a member of the research team (MJ) picked one set of
study site allocations at random from the set of all pos-
sible allocations, each contained within separate sealed
opaque envelopes.
Intervention
The TIME intervention, described here according to
guidance for intervention description and replication
(TIDieR) checklist [28], is Prenoxad—a multi-dose THN
kit containing 2mg naloxone hydrochloride 1mg/1ml so-
lution for intramuscular injection. This kit contains sim-
ple textual and pictorial instructions which reiterate
face-to-face training each participant receives as part of
the intervention. Participants will not be able to receive
part of the intervention only—e.g. the training but not
the kit—and so will need to consent to the whole inter-
vention or decline the whole intervention.
The kit is manufactured by the Martindale Pharma
(Woodburn Green, UK) and supported by ‘train-the-
trainer’ materials for participating paramedics and ED
staff developed by Stephen Malloy, an independent con-
sultant. Each Prenoxad kit retails at £21.00 before VAT
(value-added tax). The decision to use the Prenoxad kit,
as opposed to an intranasal alternative, is supported by
evidence regarding the bioavailability of naloxone follow-
ing intramuscular versus intranasal administration [29, 30]
and the time taken for improvement in respiratory rate to
be observable [31]. We also based our decision on feed-
back from drug service workers who were approached in
the initial setting up of the study.
Paramedics, nurses, and doctors at intervention site
EDs and ambulance services registered with their re-
spective professional bodies will be invited to participate
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in the study, and volunteers will be trained in delivering
the intervention in accordance with the study protocol.
Patient Group Directions (PGDs) will be established at
participating services within intervention sites to allow
non-prescribing paramedics and nurses to distribute
THN kits. Training, provided in a flexible manner to suit
the working practices of individual departments and
services, will involve face-to-face group-based training,
complemented by a ‘cascade’ approach whereby research
support paramedics and nurses continue to train their
peers on an ad hoc basis. Online resources produced by
Martindale Pharma will be available as refresher content
for staff (http://www.prenoxadinjection.com/). Training
per person will take up to 15 min. Staff will complete
Fig. 1 Overall CONSORT diagram
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and sign a ‘Record of Completion of Training’ form once
they have been deemed competent by their trainer.
At intervention sites, participating healthcare profes-
sionals based in the specific ED or ambulance service re-
gion and caring for patients eligible to receive the
intervention will offer these patients the THN kit, with an
explanation of its purpose. Patients will receive treatment
as usual (TAU) and then be offered the intervention.
TAU for suspected opioid overdose involves a clinical
assessment during which the healthcare staff who first
come into contact with the patient seek to confirm the
substance or substances which led to the overdose. Opi-
oid overdose is assumed if the substance which led to
overdose is not known and the patient presents with an
altered mental state—including reduced consciousness—
bradypnoea and miosis. Treatment includes prolonged
and gradual administration of naloxone followed by a
period of observation. Ideally, for patients attended by
ambulance services, the treatment will begin at the site
of the overdose and then continues at the ED following
conveyance. However, patients may refuse to be con-
veyed should they respond to the naloxone at the scene.
In the intervention arm, if the patient consents to re-
ceiving the kit, the healthcare professional will provide
training regarding the preparation and administration of
the naloxone dose using the kit materials. The health-
care professional and the patient will then complete a
training checklist document, to be made available to re-
search support staff and stored as evidence that training
was provided as part of the intervention.
At control sites, patients who attend for opioid poison-
ing or overdose or other drug-related problems will re-
ceive TAU (as described above) from ambulance and ED
staff and will not be offered a THN kit.
Blinding
Due to the nature of the intervention, the study will not
include blinding of participants or intervention pro-
viders. However, the study statistician will remain
blinded to allocation until the study data is ‘locked’ and
as far as proves feasible during analysis.
Outcomes
We will measure outcomes related to the feasibility of
the study in terms of the intervention and methodology,
including whether we can capture sufficient data to
measure clinical outcomes and health economics.
Outcomes related to the feasibility of the study include
sign up of sites; proportion of eligible staff recruited and
trained to deliver the intervention; proportion of eligible
participants identified, number of kits issued; and the
adverse event rate in intervention and control sites.
We will also assess the feasibility of collecting clinical
outcomes from anonymised linked routine health records
over a period of 12 months, acknowledging that feasibility
will also depend on the quality and availability of routine
data.
The proposed primary outcome is mortality (all deaths
and those known to be opioid-related). Secondary out-
comes include intensive treatment unit (ITU) admissions,
ED visits, and in-patient admissions (all visits/attendances
as well as those known to be opioid-related), further 999
calls as well as THN kits issued and costs. Our feasibility
study will not be adequately powered to detect statistically
significant differences in these proposed outcomes be-
tween intervention and control arms.
We will assess the feasibility of using routine data
sources to estimate health care costs. Total NHS costs
for each patient will be calculated based on the staff
training costs, patient training costs, and other NHS
costs (e.g. those for 999 calls, ED attendances, and ad-
missions). Training costs will be calculated using records
of completion of training, staff recall of patient training,
and then combined with NHS salary data. Other NHS
costs will be based on routine data for the relevant ED
and ambulance service trusts.
We will use qualitative data to explore the feasibility
and acceptability of THN from the perspective of service
users, based upon their previous knowledge and experi-
ence of overdose. We will also explore the feasibility and
acceptability of the intervention from the provider per-
spective by undertaking interviews and focus groups
with paramedics, clinical ED staff, and health service
managers at participating sites regarding THN in emer-
gency settings. We will explore awareness and experi-
ences of naloxone, perceived benefits and challenges of
THN, and views on the feasibility and acceptability of
distributing THN via ambulance paramedics and hos-
pital EDs. Interviews will be recorded, with participants’
consent, and professionally transcribed prior to analysis.
We will use normalisation process theory (NPT) to
guide analysis of the provider data and to help under-
stand how the intervention can be optimised within the
ED and prehospital settings, and to explore whether dif-
ficulties in implementation are due to the intervention
itself or due to other factors.
Progression criteria
We will decide whether or not to proceed to a fully pow-
ered RCT using the following assessment principles and
progression criteria:
 Green: indicates that we have either met a criterion
(in which case no modifications to the relevant
aspect of the study protocol may be needed) or we
are within 10% of our stated progression targets (in
which case we will review the reasons for this and
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consider appropriate modifications to study
methods)
 Amber: indicates that we are within 20% of our
stated progression target, in which case we will
critically review reasons for this and assess whether
major changes to study methods are likely to realise
significant improvements
 Red: indicates that we are more than 20% from our
target, in which case we will not, in the absence of
clear extenuating circumstances, consider
progression to a full trial
All the percentage changes will be measured as relative.
Intervention feasibility
1. Sign up of four sites, including ≥ 50% eligible staff
to complete training in delivering the intervention
at each intervention site
2. Identification of ≥ 50% of people who have
presented to ED or ambulance service with opioid
overdose or an opioid use related problem
3. THN kits offered to ≥ 50% eligible patients at
intervention sites
4. Serious adverse event rate of no more than 10%
difference between intervention and control sites
during the live trial period and prior to the
conclusion of data collection
Trial method feasibility
1. Identification and inclusion for outcome follow-up
of ≥ 75% of people who died of opioid poisoning in
the following year
2. Matching and data linkage in ≥ 90% of cases not
dissented at the conclusion of quantitative data
collection
3. Retrieval of primary and secondary outcomes for ≥
75% of included participants from NHS Digital and
National Welsh Informatics Service within 1 year of
the projected timeline
Safety monitoring
We will regard data on service usage (emergency and
ITU admissions, and emergency attendances) and death
as surrogate markers of adverse behavioural change in
relation to opioid misuse, such as taking larger doses at
one time. In doing so, we assume that increased rates of
service usage and death correlate with an increased vol-
ume of higher risk drug-taking behaviour. We will also
monitor for instances of serious adverse events, includ-
ing deaths following THN use by interrogating routine
health service data and also requests for data made to
services on behalf of coroners across intervention and
control sites. We include control sites because we expect




To develop the discriminant function to be used for de-
fining our population for outcome comparison, we will
partition the available routine (retrospective) linked
dataset, using one part (training data) to determine in-
clusion thresholds and the other (testing data) to check
the performance of the function. We will use the actual
number of recorded opioid poisoning deaths during the
trial period to validate the function. We will summarise
performance by calculating sensitivity (the proportion of
actual opioid poisoning deaths included in our defined
high-risk population; denominator = all actual opioid
poisoning deaths, a/a+c) and positive predictive value
(the proportion of our defined the high-risk population
who die of opioid poisoning in the following year; de-
nominator = all defined high risk, a/a+b) as shown in
Table 1.
We will report on whether our discriminant function
can, via Fisher’s linear discriminant function, be usefully
reduced to a single individual-level risk score, consider
thresholds used in its definition, and evaluate its per-
formance as a predictive tool using test datasets com-
piled specifically for this purpose.
Study data
Our primary analyses will address the progression cri-
teria as presented above and will be largely descriptive in
nature. We will develop a formal Statistical Analysis Plan
(SAP) to outline all planned analyses, including conven-
tions on the treatment of missing data, principles of selec-
tion of explanatory factors and covariates in statistical
models, and the reporting of raw and adjusted outcomes.
We will produce a CONsolidated Standards Of
Reporting Trials (CONSORT) flowchart for patient re-
cruitment appropriate for cluster trials [32]. Study data
will be summarised by intervention or control arm, and
we will further summarise key demographic and out-
come variables by study site. Although this feasibility
study is not intended to provide a definitive evaluation
of the THN intervention, we will assess and report
Table 1 Sensitivity and positive predictive value of a
discriminant function
Actual opioid death No opioid death
Predicted high risk a b a+b
Not predicted high risk c d c+d
a+c b+d
Jones et al. Pilot and Feasibility Studies            (2020) 6:96 Page 7 of 10
differences in outcomes via appropriate generalised
mixed linear models, adjusting for key covariates and
factors.
For the follow-up population (B), we will also summar-
ise linkage rates and characteristics for those not linked
versus those linked, coding completion rates for ED and
ambulance service events, and carry out a comparison of
data obtained from routine sources. We will report these
data by site and in total. We will provide details on data
completeness related to the criteria for determining pro-
gression to a full trial.
Qualitative data
We will use NVIVO to manage the qualitative data and
carry out a thematic analysis of interview transcripts.
Transcripts will be imported into NVIVO and be read
and re-read to ensure familiarity with the data before
coding. One researcher will develop and refine initial
codes, with coding undertaken both with reference to
NPT as a theory for evaluating the potential for normal-
isation of the intervention as a change of working prac-
tices in emergency settings [33] and ‘grounded’ in the
data. Codes will be reviewed and emerging concepts
used to develop themes. A second researcher will inde-
pendently code a subsample of transcripts for compari-
son and discussion before further refinement of the
coding structure and themes by the first researcher. Pa-
tient and public involvement (PPI) members will be in-
volved in the qualitative analysis by co-developing
themes and reviewing drafts of findings. Data from ser-
vice providers at intervention sites will be compared
within sites across time and also between sites for com-
monalities and divergence in themes.
Trial management
A Trial Management Group (TMG) will manage the
project and report to the independent Trial Steering
Committee (TSC) at appropriate intervals. The Chief In-
vestigator will chair the TMG which will meet every 3
months. The TMG will comprise all co-applicants,
named collaborators, PPI members, and researchers.
The TSC will oversee the conduct and progress of the
trial and adherence to the protocol, patient safety, and
the consideration of new information of relevance to the
trial. Two PPI members are full members of the TSC.
A Data Monitoring Committee (DMC) will monitor
study data at interim periods and make recommenda-
tions to the TSC on whether there are any ethical or
safety reasons why the trial should not continue. Its
members will have access to comparative data and in-
terim analyses and may request the un-blinding of such
data at any time. The DMC will also consider requests
for the release of data. The DMC may be asked by the
TSC, Trial Sponsor, or Study Funder to consider data
emerging from other related studies. If new evidence be-
comes available during the course of the trial, it is the
responsibility of the trial and/or Data Manager to pro-
vide that information to the DMC to allow them to con-
sider such issues and make recommendations on the
continuation of the trial to the TSC.
Any risks identified throughout the trial will be docu-
mented in a risk log and monitored. This will be re-
ported to the TMG and escalated to the TSC if
appropriate.
Public and patient involvement
We have involved public and patient members through-
out this study to strengthen research rigour [34]. PPI
members have experience of opioid addiction through
family and voluntary networks. They have contributed to
developing this study using personal experience to high-
light the relevance of the research questions and com-
ment on data collection methods and selection of
outcomes. We also discussed the project with drug ser-
vice users and voluntary sector service providers in the
community. PPI members were named as co-applicants
on the funding proposal. They will remain involved as
members of the Trial Management Group and relevant
subgroups. They will contribute to study management,
reporting and dissemination through papers. Addition-
ally, we have recruited two more individuals with rele-
vant experience to be involved in the Trial Steering
Committee. We will support all public and patient mem-
bers to collaborate as equal members throughout the
study [35].
Dissemination
In addition to publishing results in scientific journals, we
will engage with third sector organisations, and media
and communication departments at participating institu-
tions, and we will disseminate findings and raise aware-
ness about the trial and wider issues related to
implementation. We will develop a proposal for funding
for a fully powered trial, should this be supported by our
findings.
Discussion
This study is the first to our knowledge to use routine
anonymised linked data to identify the target population
and measure outcomes related to a peer administered
anti-overdose intervention such as THN in emergency
settings. Our novel approach to capturing outcome data
comes from the public health nature of the intervention,
which is administered by laypeople to their peers who
may or may not be the original recipient of the THN kit,
as well as our own previous research indicating that
individuals within the target population for the intervention
Jones et al. Pilot and Feasibility Studies            (2020) 6:96 Page 8 of 10
move around a lot and are very difficult to follow-up using
traditional methods.
The strength of this study lies in its novel approach es-
tablishing evidence in a new setting for an intervention
which is already being distributed, albeit patchily, in re-
sponse to opioid overdose as a growing public health
concern. The study is being carried out by a team well
placed to apply expertise and prior experience in the use
of routine data in RCTs to contribute to the evidence
base for THN in emergency settings, which is in urgent
need of strengthening.
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